European Wax Center beats fiscal 2022 guidance on center openings and system-wide sales

European Wax Center, Inc.

Preliminary 2022: 91 net new center openings vs. guidance of 88-90.
System-wide sales of $898.6M exceeded outlook of $885-895M.
Expects total revenue and same-store sales (approx. 9.5%) above prior high end.
Adjusted EBITDA expected at high end of $70-71M; adjusted net income at high end of $27.5-28.5M.
Repurchased ~700K shares for $10M in Q4; $30M remains under buyback program.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

European Wax Center, Inc. reported fiscal year ended December 31, 2022 results: revenue Total revenue above the high end of previous outlook of $202 million to $205 million, net income Adjusted net income at the high end of previous outlook of $27.5 million to $28.5 million. Guidance raised.

Period: fiscal year ended December 31, 2022
Revenue: Total revenue above the high end of previous outlook of $202 million to $205 million
Net income: Adjusted net income at the high end of previous outlook of $27.5 million to $28.5 million
Guidance: raised
Result: preliminary results

Exact text from the filing

, exceeding previous outlook of $885 million to $895 million The Company expects to deliver fiscal 2022 results of: • Total revenue above the high end of previous outlook of $202 million to $205 million • Same-store sales above the high end of previous outlook of approximately 9.5% • Adjusted net income at the high end of previous outlook of $27.5 million to

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

European Wax Center, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000525

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.